



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/603271/2015

## European Medicines Agency decision

P/0223/2015

of 2 October 2015

on the granting of a product specific waiver for hydromorphone (hydrochloride) / naloxone (hydrochloride) (EMA-001762-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

P/0223/2015

of 2 October 2015

on the granting of a product specific waiver for hydromorphone (hydrochloride) / naloxone (hydrochloride) (EMA-001762-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Mundipharma Research GmbH & Co. KG on 29 April 2015 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 August 2015 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A waiver for hydromorphone (hydrochloride) / naloxone (hydrochloride), prolonged-release capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Mundipharma Research GmbH & Co. KG, Höhenstraße 10, 65549 – Limburg, Germany.

Done at London, 2 October 2015

For the European Medicines Agency  
Jordi Llinares Garcia  
Head of Division (ad interim)  
Human Medicines Research and Development Support  
(Signature on file)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/386460/2015  
London, 14 August 2015

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001762-PIP01-15

### Scope of the application

**Active substance(s):**

Hydromorphone (hydrochloride) / naloxone (hydrochloride)

**Condition(s):**

Treatment of pain

Treatment of opioid-induced constipation

**Pharmaceutical form(s):**

Prolonged-release capsule, hard

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Mundipharma Research GmbH & Co. KG

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Mundipharma Research GmbH & Co. KG submitted to the European Medicines Agency on 29 April 2015 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 16 June 2015.



## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report :

- to grant a product-specific waiver for all subsets of the paediatric population for the above mentioned condition(s) in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. Waiver

## 1.1. Condition:

Treatment of pain

The waiver applies to:

- the paediatric population from birth to less than 12 years of age;
- prolonged-release capsule, hard, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- the paediatric population from 12 to less than 18 years of age;
- prolonged-release capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

## 1.2. Condition:

Treatment of opioid-induced constipation

The waiver applies to:

- the paediatric population from birth to less than 12 years of age;
- prolonged-release capsule, hard, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- the paediatric population from 12 to less than 18 years of age;
- prolonged-release capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.